about
Economic cost of autism in the UKStudy protocol for a randomised pragmatic trial comparing the clinical and cost effectiveness of lithium and quetiapine augmentation in treatment resistant depression (the LQD study)Study of the use of antidepressants for depression in dementia: the HTA-SADD trial--a multicentre, randomised, double-blind, placebo-controlled trial of the clinical effectiveness and cost-effectiveness of sertraline and mirtazapine.Improving Well-being and Health for People with Dementia (WHELD): study protocol for a randomised controlled trial.Cognitive remediation therapy in schizophrenia: randomised controlled trial.The treatment of challenging behaviour in intellectual disabilities: cost-effectiveness analysis.Annotation: Economic evaluations of child and adolescent mental health interventions: a systematic review.Cost effectiveness of a manual based coping strategy programme in promoting the mental health of family carers of people with dementia (the START (STrAtegies for RelaTives) study): a pragmatic randomised controlled trial.Quality-of-life assessment in dementia: the use of DEMQOL and DEMQOL-Proxy total scores.Predictors of care home and hospital admissions and their costs for older people with Alzheimer's disease: findings from a large London case register.Economic evidence in intellectual disabilities: a review.Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial.Dementia care costs and outcomes: a systematic review.Development of DEMQOL-U and DEMQOL-PROXY-U: generation of preference-based indices from DEMQOL and DEMQOL-PROXY for use in economic evaluation.A pilot randomised controlled trial of community-led ANtipsychotic Drug REduction for Adults with Learning Disabilities.START (STrAtegies for RelaTives) study: a pragmatic randomised controlled trial to determine the clinical effectiveness and cost-effectiveness of a manual-based coping strategy programme in promoting the mental health of carers of people with dementThe cost of care homes for people with dementia in England: a modelling approach.Economic Evaluation of Mental Health Interventions: A Guide to Costing Approaches.Urban adolescents with intellectual disability and challenging behaviour: costs and characteristics during transition to adult services.Epidemiology of Pain in People With Dementia Living in Care Homes: Longitudinal Course, Prevalence, and Treatment Implications.Long-term clinical and cost-effectiveness of psychological intervention for family carers of people with dementia: a single-blind, randomised, controlled trial.Reported goal setting and benefits of person centred planning for people with intellectual disabilities.The cost-effectiveness of mirtazapine versus paroxetine in treating people with depression in primary care.Manualised Individual Cognitive Behavioural Therapy for mood disorders in people with mild to moderate intellectual disability: a feasibility randomised controlled trial.Neuroleptics in the treatment of aggressive challenging behaviour for people with intellectual disabilities: a randomised controlled trial (NACHBID).Cost-effectiveness analyses for mirtazapine and sertraline in dementia: randomised controlled trial.Cost-effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO-AD trial).Feasibility of a staff training and support programme to improve pain assessment and management in people with dementia living in care homes.Lean economies and innovation in mental health systems.Dependence in Alzheimer's disease and service use costs, quality of life, and caregiver burden: the DADE study.Impact of person-centred care training and person-centred activities on quality of life, agitation, and antipsychotic use in people with dementia living in nursing homes: A cluster-randomised controlled trial.Treatment and prevention of depression after surgery for hip fracture in older people: cost-effectiveness analysis.Service use and cost of mental disorder in older adults with intellectual disability.Economic cost of severe antisocial behaviour in children--and who pays it.Randomized, single-blind, controlled trial of a specialist behavior therapy team for challenging behavior in adults with intellectual disabilities.Applied behaviour analysis and standard treatment in intellectual disability: 2-year outcomes.Cognitive remediation therapy in schizophrenia: cost-effectiveness analysis.Cost estimation of a health-check intervention for adults with intellectual disabilities in the UK.Cost-effectiveness of transcranial magnetic stimulation vs. electroconvulsive therapy for severe depression: a multi-centre randomised controlled trial.Outcomes and costs of community living: semi-independent living and fully staffed group homes.
P50
Q28241419-5CBDF27A-E10E-434A-836A-920CE6D73A6BQ33837167-FCB3B2BA-D01A-4981-9455-91D7B0E4D728Q34329621-87DCE0E0-75D7-413F-A41C-CB343D9D9E2AQ34485968-FF61D135-5FE5-4297-AF32-B897FABF0767Q34624476-50AF6A1D-869D-45F4-A944-9FD117FFEB73Q34982370-80D97C92-FFC2-4C5C-975E-6EC494738A86Q36234219-C7A4C383-AD87-46F0-9124-05DAE7178F9CQ37254686-69958207-E48F-43BB-96CC-59D1A5EF4A01Q37405147-C98B93F7-CA75-4EBC-A027-5D0A22687C5EQ37454280-DDFA0B08-E355-4550-9275-FB2BDC4F6995Q37780177-EA81D688-11A6-4E15-8BE1-A31422C39D29Q37901878-436085E2-9232-48C5-B8AC-BC5C5635AC07Q38034164-9EA548C8-0DFB-4038-869D-DE12934DDEBAQ38080899-304CB17E-4098-49FD-B4C5-9963312BE988Q38600378-ACED6026-042E-4EFE-AAC9-A0A5626FE76CQ39116289-771CE98B-7AB9-4FD2-BAFC-CB20159DE61FQ39136589-9F0EBEFD-1295-4C32-B3F8-ADA8B4EB493CQ39963564-4161394A-607E-413E-805B-52CD6EDF7C26Q40091507-0BF88010-6F29-4E81-B3AD-2B43603E5797Q40279620-DAA30972-58E2-48AC-B230-AAADA26C694FQ40548927-9F095813-A942-46C5-9E47-7523BA88C4ADQ42656276-3F5C043D-1CF9-4211-8573-265F52CBB2CDQ44859484-481F9495-E23E-4C21-9E26-DA7026328FB8Q46001799-6E954102-19C7-45D3-91F8-A092C0496E58Q46034924-57680F4F-DEE2-4D09-921C-47B2AD451B4AQ46797912-413F88EC-4F5A-4159-9B43-43C25785FC63Q47163824-568262B6-E4B5-413C-83D4-005364F865C9Q47731554-E7C3480C-A47E-431D-A401-07E53509907FQ48035770-BDA42EA5-BA44-464E-9D62-D6F0E35FDAE2Q48069635-230A0F1F-DDC9-4001-B84F-0FE77EF6B937Q48097486-4E693A4B-E20B-4BBF-81BC-B767C0D95F26Q49090899-E64ED15F-E073-407B-B8BB-CD221DBDBB35Q50439466-2E02C488-F7EE-4E22-8682-36C386DAFABDQ50782981-F016D549-241B-4F37-8209-04D0097EE52FQ51619807-E4716223-BE53-4D25-AF69-2B6CA758B468Q51824298-DEA09FA2-C925-4D4F-AC08-4918533A3C96Q51857988-3C2BBAE1-42AC-462E-A1D9-E3A9268206DDQ51872021-CF24B059-82E4-4BEB-B022-E8015C070D4CQ51894034-0235BA46-E8C7-43A1-A5B6-6882C8C9D6DFQ51894347-07B2CE88-A47C-40C3-9C51-6637E1839616
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
ricercatrice
@it
հետազոտող
@hy
name
Renee Romeo
@ast
Renee Romeo
@en
Renee Romeo
@es
Renee Romeo
@nl
Renee Romeo
@sl
type
label
Renee Romeo
@ast
Renee Romeo
@en
Renee Romeo
@es
Renee Romeo
@nl
Renee Romeo
@sl
prefLabel
Renee Romeo
@ast
Renee Romeo
@en
Renee Romeo
@es
Renee Romeo
@nl
Renee Romeo
@sl
P214
P244
P1053
E-3261-2010
P106
P1153
56281591300
P21
P214
P244
nb2009021680
P31
P3829
P496
0000-0003-3871-9697
P734
P7859
lccn-nb2009021680